Immune therapy for type 1 diabetes mellitus-what is unique about anti-CD3 antibodies?
about
Reversal of type 1 diabetes via islet β cell regeneration following immune modulation by cord blood-derived multipotent stem cellsInducing and Administering Tregs to Treat Human DiseaseAntigen-based immunotherapy for autoimmune disease: current statusThe Juvenile Diabetes Research Foundation at forty: updates of research in type 1 diabetes.Adaptive immune regulation of glial homeostasis as an immunization strategy for neurodegenerative diseasesNovel therapies for coeliac diseaseEvaluating preclinical efficacy.Mapping I-A(g7) restricted epitopes in murine G6PC2.CD28⁻ CD8⁺ T cells are significantly reduced and correlate with disease duration in juveniles with type 1 diabetes.Therapeutic use of a selective S1P1 receptor modulator ponesimod in autoimmune diabetesTeplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.The importance of the Non Obese Diabetic (NOD) mouse model in autoimmune diabetesPreexisting autoantibodies predict efficacy of oral insulin to cure autoimmune diabetes in combination with anti-CD3.Potent induction immunotherapy promotes long-term insulin independence after islet transplantation in type 1 diabetesThe use of peptide-major-histocompatibility-complex multimers in type 1 diabetes mellitus.Prevention of Type 1 Diabetes Mellitus using a Novel Vaccine.New and future immunomodulatory therapy in type 1 diabetes.Exercise to preserve beta cell function in recent-onset type 1 diabetes mellitus (EXTOD)--a study protocol for a pilot randomized controlled trialOligofructose as an adjunct in treatment of diabetes in NOD mice.The potential of multimer technologies in type 1 diabetes prediction strategies.Immunomodulatory therapy to preserve pancreatic β-cell function in type 1 diabetes.Autoimmunity and inflammation: murine models and translational studies.Connecting type 1 and type 2 diabetes through innate immunity.Future treatment strategies for celiac disease.Clinical immunologic interventions for the treatment of type 1 diabetes.The potential role of dendritic cells in the therapy of Type 1 diabetes.CD3 monoclonal antibodies: a first step towards operational immune tolerance in the clinic.Treatment of new onset type 1 diabetes with teplizumab: successes and pitfalls in development.Teplizumab induces human gut-tropic regulatory cells in humanized mice and patients.Reestablishing T Cell Tolerance by Antibody-Based Therapy in Type 1 Diabetes.Anti-CD3ε mAb improves thymic architecture and prevents autoimmune manifestations in a mouse model of Omenn syndrome: therapeutic implications.Genetic variants regulating immune cell levels in health and disease.Membrane-bound Dickkopf-1 in Foxp3+ regulatory T cells suppresses T-cell-mediated autoimmune colitis.Anti-CD3 mAb treatment cures PDL1-/-.NOD mice of diabetes but precipitates fatal myocarditis.Humanizing animal models: a key to autoimmune diabetes treatment.The case for an autoimmune aetiology of type 1 diabetes.Low doses of anti-CD3, ciclosporin A and the vitamin D analogue, TX527, synergise to delay recurrence of autoimmune diabetes in an islet-transplanted NOD mouse model of diabetes.Low-dose anti-CD3 antibody induces remission of active autoimmune hepatitis in xenoimmunized mice.Contrast-enhanced ultrasound measurement of pancreatic blood flow dynamics predicts type 1 diabetes progression in preclinical models.
P2860
Q21245299-2E19FD5D-EE2D-4EEB-A064-47CF40639B1BQ26772723-3BF23610-B505-4D7F-B5A7-DCBADF4B022BQ26852915-A570B9CC-921E-4136-B779-E90F80C6C91DQ33930175-B922592B-1871-484B-AB26-F15A408E33EEQ34071942-67E66349-EA94-4504-87B8-279A03A7DAE6Q34170574-E9FE18DE-7369-435C-A062-3B6E50B5E7FFQ34208736-AF701A29-4216-4AFD-8473-AB6524AEADBEQ34415712-F376E27A-D659-490A-A67A-7E655A099F27Q34763554-07E576B1-BEDD-46D7-81A5-DD7BCF9D46B6Q35035148-F40F6CD5-C4D0-44BC-861A-2FCFDAFF023BQ35321191-E3FA9BE0-8EF4-4C6C-8BC3-B43D2F5384A0Q35787117-4ADBA4BB-A489-4026-AFB5-80DC45C8CDFFQ35976614-CDB416E5-47BB-49C9-BAF4-6EB2F54C0751Q36077883-8E989DAA-53D5-43B9-9C41-B51CF26FA70DQ36228996-C9A4CA85-3D8B-4EC6-B78A-0114CC008754Q36327992-4A24789A-1680-4EA9-A011-0B0D351D4F10Q36650474-F3B05FD0-339A-4953-B88B-BD502542B001Q36958167-71D4498C-64FD-4A07-9861-7C6CC7B561F6Q37428004-630EF7B1-B6F4-45F7-B863-94BCC9D1ABFAQ37838895-AD418190-D008-4E47-AA45-1DC83F58A943Q37883029-B6D2B1A3-8594-4FE3-9E1D-BF779A47C1AAQ37891882-9A425956-61A1-4F1D-9046-D75360BA6571Q37990919-EA9201B7-590F-4A08-9E75-077AECE1C68AQ38012460-2DCED22A-9546-4A20-8962-60728CCD4AC5Q38036230-EC22BB03-9083-46EC-8908-F3A28D3F7CEDQ38110933-6F523B20-57A1-4E95-9A94-E4D8CEC7788DQ38117284-17C2053F-DC11-4FD8-BB5E-DBA3D29B236CQ38187146-0E795D13-7983-449E-921B-A445B251F182Q38328280-41B1C801-3A8F-4621-BDBC-4C058A0A954AQ38384138-53FE9343-7D54-4685-A55F-78EDA218E5C8Q39598202-FE54562A-24C6-496C-BF6F-DE1AB348E559Q41229283-8F0DB158-9339-4029-9841-69161A4E65A9Q41589465-182D2446-F9F2-46E7-97A1-A696E3CE12BDQ42103691-22898317-1B16-45A5-A2FB-E253CDC02B16Q42818772-54B8849F-DE7C-401E-9405-1C0614A02902Q44420822-9D09C04D-0A1A-497E-B831-3ED1A213DE36Q50948559-2647928E-F3C2-455A-8BD3-A23C92810343Q53067044-4374E6E9-5FCE-4B68-A717-61D969FC732CQ55083872-0CD60F89-1F24-4A29-9BED-A0937B9036C5
P2860
Immune therapy for type 1 diabetes mellitus-what is unique about anti-CD3 antibodies?
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Immune therapy for type 1 diabetes mellitus-what is unique about anti-CD3 antibodies?
@ast
Immune therapy for type 1 diabetes mellitus-what is unique about anti-CD3 antibodies?
@en
Immune therapy for type 1 diabetes mellitus-what is unique about anti-CD3 antibodies?
@nl
type
label
Immune therapy for type 1 diabetes mellitus-what is unique about anti-CD3 antibodies?
@ast
Immune therapy for type 1 diabetes mellitus-what is unique about anti-CD3 antibodies?
@en
Immune therapy for type 1 diabetes mellitus-what is unique about anti-CD3 antibodies?
@nl
prefLabel
Immune therapy for type 1 diabetes mellitus-what is unique about anti-CD3 antibodies?
@ast
Immune therapy for type 1 diabetes mellitus-what is unique about anti-CD3 antibodies?
@en
Immune therapy for type 1 diabetes mellitus-what is unique about anti-CD3 antibodies?
@nl
P356
P1476
Immune therapy for type 1 diabetes mellitus-what is unique about anti-CD3 antibodies?
@en
P2860
P2888
P304
P356
10.1038/NRENDO.2009.275
P577
2010-03-01T00:00:00Z